ADC Therapeutics Signs a License Agreement with Adagene for its SAFEbody Technology

 ADC Therapeutics Signs a License Agreement with Adagene for its SAFEbody Technology

ADC Therapeutics Signs a License Agreement with Adagene for its SAFEbody Technology

Shots:

  • Adagene to receive upfront, development & commercial milestones, research funding and royalties on sales with certain commercialization rights for Greater China.  ADC Therapeutics to utilize Adagene’s SAFEbody technology generating Abs that will further combine with its pyrrolobenzodiazepine (PBD) cytotoxic payload technology to develop masked ADCs for solid tumors
  • ADC Therapeutics also has an option to utilize SAFEbody technology for one additional exclusive target. The programs will focus on the targets in which healthy tissue expression prevent the development of ADCs
  • SAFEbody technology produces masked ADCs that binds with an antigen in tumor tissues only enhancing the specificity of an ADC with minimization in off-target toxicity on healthy cells

Click here to read full press release/ article | Ref: ADC Therapeutics | Image: ADCReview

Tuba Khan

Tuba Khan is an Editor and Digital Marketing expert at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in Lifesciences industry. She covers Pharma, Medical devices, Diagnostics and Digital health segment. Tuba also has an experience of digital and social media marketing and can run the campaign independently. She is also certified as a Digital marketer and social media marketer. She can be contacted on tuba@pharmashots.com

Related post